HLB Pharmaceutical Decides on 19 Billion KRW Capital Increase
On April 24, HLB Pharmaceutical announced that it will conduct a third-party allotment capital increase worth 19 billion KRW. The purpose of this new share issuance is to raise funds for operating capital and other financial needs. The issue price for the new shares is 19,460 KRW per share. A total of 976,362 common shares will be issued. All of the newly issued shares will be allotted to HLB Life Science, the largest shareholder.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Is Yours Just Gathering Dust at Home? Millennials & Gen Z Rediscover Digicams O...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- "I Take Full Responsibility"... Seongjae Ahn Issues Direct Apology for 'Wine Swi...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
